Fundz

Trautec Completes Rmb 200 Million Series B Fundraise Led By L Catterton

PRIVATESep 28, 2023

Round Type

Series B

ManufacturingBiotechnology

Investors

L Catterton

Description

Trautec, a pioneer and market leader in China's synthetic recombinant human collagen ("SRHC") industry, today announced that it has completed a RMB 200 million ($27 million) Series B fundraise led by L Catterton, a leading global consumer-focused investment firm. The successful fundraise positions Trautec to cement its pole position in the country and accelerate its international expansion amid the broadening use of SRHC in skincare products, as well as medical dressings and aesthetic treatments.

Quick answer

Trautec raised an undisclosed amount in a Series B round, dated September 28, 2023. Investors: L Catterton.

How much did Trautec raise?
Trautec raised an undisclosed amount in a Series B round on September 28, 2023.
Who invested in Trautec?
L Catterton is named as investors in this round.
What does Trautec do?
Established in 2015, Trautec is dedicated to the development and production of recombinant collagen based (SRHC) biomaterials for mainly medical and cosmetics industries.
Who are the decision-makers at Trautec?
Fundz holds 1 contact at Trautec. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Manufacturing and Biotechnology around the same time

Companies in the same sectors as Trautec that raised within 45 days of this round, from Fundz verified event records.

  • SURGLASSES raised $6.5M (Funding Round) on November 9, 2023.
  • Letoon Holding Ltd raised $25M (Funding Round) on November 8, 2023.
  • Nature's Toolbox raised $44M on November 7, 2023.
  • Okami Medical raised $5M on November 7, 2023.
  • Genezen raised $19M (Private Equity) on November 2, 2023.
  • TendoNova raised $250K on November 1, 2023.

Who to call at Trautec, and when

A new round usually means Trautec is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Trautec raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Trautec, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Trautec. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Trautec

About

Established in 2015, Trautec is dedicated to the development and production of recombinant collagen based (SRHC) biomaterials for mainly medical and cosmetics industries. SRHC produced by biosynthesis is non-animal produced collagen. As the pioneer of the industry, Trautec operates the full value chain from R&D, manufacturing, to distribution, by holding multiple intellectual property rights in the development of recombinant collagen, and owning its production plant located in Jiangsu, China. The market of functional skincare, which offers specific functions to skin, is growing significantly as more and more consumers are looking for effective solutions to their skin problems. The needs for recombinant collagen are expanding because of its stability and effectiveness as well as wide application to medical, healthcare and cosmetics fields. In 2022, the Shiseido Beauty Innovation Fund invested into Trautec and form a full strategic partnership between Shiseido and Trautec to work together in all areas including product search and development, raw material supply, and sales channels to exploration of new areas in functional skincare. In 2023, the B-round financing has been successfully signed. The round was jointly led by L Catterton, the world’s largest consumer-focused private equity firm under LVMH. This round of financing will mainly be used for industrialization promotion, innovative technology research and development, and overseas market expansion. Trautec continues to expand the application of SRHC in high-end fields including medicine, medical regeneration, and aesthetics, and occupy the forefront of the industry.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Trautec raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Trautec's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Trautec raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.